Artrya Receives UK regulatory approval for Salix V2.0 software
- Artrya (AYA) receives regulatory approval for its Salix Coronary Anatomy (SCA) product in the United Kingdom from the European Notified Body (BSI)
- The BSI found that the company’s Salix V2.0 software had met or exceeded all regulatory requirements and has recommended the software for marketing into the UK
- With the new approval, the platform is now able to approach hospitals as part of its four-year contract with the SCA product to finalise arrangements for the product roll out
- The company said other business development activities in the UK are well advanced for use of the SCA product within clinical practices outside of the NHS network
- Shares in the company end the day 3.03 per cent in the red to close at 64 cents
